Jason Rhodes Sells Shares of Dyne Therapeutics
Jason Rhodes sold 309,268 shares of Dyne Therapeutics, Inc., valued at $6.58 million.
Key Points
- Jason Rhodes sold 309,268 shares of Dyne Therapeutics, Inc. on June 26, 2026, for approximately $6.58 million.
- Dyne Therapeutics, Inc. has a market cap of around $3.46 billion and a 52-week range of $8.06 to $25.00.
- Analysts maintain a strong buy consensus with a target mean price of $38.25 for Dyne Therapeutics, Inc.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Jason Rhodes, a significant insider at Dyne Therapeutics, Inc. (NasdaqGS: DYN), sold 309,268 shares of the company on June 26, 2026. The transaction, which was planned, amounted to approximately $6.58 million, with each share priced at $21.28.
Insider Buying and Selling at Dyne Therapeutics, Inc.
Jason Rhodes has been actively selling shares of Dyne Therapeutics. In addition to the June 26 transaction, he sold 195,427 shares on June 29 at an average price of $21.14, and 24,100 shares on June 25 at $21.10. These sales were also planned. Another insider, Erick Lucera, the Chief Financial Officer, sold 2,362 shares on June 25 at $20.37, but this was not under a planned sale.
Dyne Therapeutics, Inc. Stock Down 12.7%
Shares of Dyne Therapeutics, Inc. traded near $21.26 on Wednesday. The company has a market cap of about $3.46 billion and is not currently profitable, resulting in no meaningful P/E ratio. Dyne's stock has seen a 52-week low of $8.06 and a high of $25.00. It maintains a 50-day moving average of $18.41 and a 200-day moving average of $17.85. The company's current ratio is strong at 19.92, with a quick ratio of 18.97 and a debt-to-equity ratio of 19.50.
$DYN stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Analysts have maintained a strong buy consensus for Dyne Therapeutics, Inc., with a target mean price of $38.25. On May 15, 2026, Evercore ISI Group maintained a buy rating with a $33.00 price target. Bernstein, on May 13, 2026, maintained a hold rating with a target of $24.00. Other firms like Chardan Capital and Morgan Stanley have also maintained buy ratings with targets as high as $50.00.
About Dyne Therapeutics
Dyne Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts. It focuses on developing therapeutics for neuromuscular diseases, including myotonic dystrophy type 1 and Duchenne muscular dystrophy, using its FORCE platform. Led by CEO John G. Cox, the company employs 263 people and is working on treatments for rare muscle diseases.
Bottom Line
Jason Rhodes' recent sale of Dyne Therapeutics shares is part of a planned series of transactions. The company's stock performance remains strong, with a market cap of $3.46 billion and a promising analyst outlook. Investors will continue to watch for updates on its therapeutic developments and financial performance.
Get Dyne Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $DYN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.